- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02880215
Development of Attention Bias Modification for Depression
October 14, 2019 updated by: Christopher G. Beevers, University of Texas at Austin
Although negatively biased attention has a central theoretical and empirical role in the maintenance of depression, there are few behavioral treatments that successfully target and improve this deficit.
The current proposal builds upon prior work and aims to further develop an attention bias modification intervention.
The investigators propose to develop a highly specific intervention that directly targets negative attention bias and the neurobiology that supports it, using cutting-edge cognitive neuroscience to inform treatment development and improve quality of life of patients whose psychopathology is maintained by negative attention bias.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The overall goal of this project is to continue development of an attention bias modification (ABM) intervention that targets and reduces negative attention bias among adults with elevated symptoms of depression.
The investigators' prior work indicates that attention bias for negative information is associated with the maintenance of depression and that neural circuitry within frontal-parietal brain networks supports biased attention for negative information, thus allowing us to develop specific and targeted interventions that directly alter the neurobiology of negative attention bias.
The proposed R33 study builds upon the investigators' prior National Institute of Mental Health (NIMH) funded work (R21MH092430), which examined whether ABM reduces negative attention bias and improves symptoms of depression.
Findings indicate that compared to placebo ABM, active ABM reduced negative attention bias and increased resting state connectivity within a neural circuit (i.e., middle frontal gyrus and dorsal anterior cingulate cortex) that supports control over emotional information.
Further, change in negative attention bias from pre- to post-ABM was significantly correlated with depression symptom change but only in the active training condition.
Importantly, a 40% decrease in symptoms was observed in the active training condition; however, similar symptom reduction was also observed in the "placebo ABM" condition.
Exploratory analyses indicated that placebo training may have promoted depression improvement by enhancing sustained attention.
Although these preliminary findings are encouraging and demonstrate that ABM successfully alters the treatment target (i.e., negative attention bias), the investigators' prior work is among the first to document efficacy of ABM among adults with clinically significant depression.
It is now prudent and necessary to obtain additional efficacy evidence for ABM before moving forward with large-scale clinical trials of ABM for depression.
Aim 1 is to conduct a randomized clinical trial among adults with elevated symptoms of depression and a negative attention bias that compares the efficacy of active ABM to cognitive control training and an assessment-only control condition that does not involve any ABM procedures.
Aim 2 is to examine whether ABM alters negative attention bias and functional connectivity within frontal-parietal neural circuitry that support negative attention bias.
Aim 3 is to identify mechanisms responsible for the putative efficacy of active ABM and cognitive control training.
Study Impact: The current project proposes to target and reduce negative attention bias with a novel intervention grounded in basic psychopathology research.
The investigators believe this experimental medicine approach will lead to the development of a highly specific and targeted intervention, using cutting-edge cognitive neuroscience to inform treatment development, and improve the quality of life of people whose psychopathology is maintained by negative attention bias.
Study Type
Interventional
Enrollment (Actual)
145
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Texas
-
Austin, Texas, United States, 78712
- Mood Disorders Laboratory
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 40 years (ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- able and willing to provide informed consent;
- fluent in English;
- moderate or greater depression symptoms;
- attention bias for negative stimuli;
- stable psychiatric and neurological medication usage.
Exclusion Criteria:
- meets criteria for current substance use disorder (mild or greater severity), current or past psychotic disorder, bipolar disorder, or schizophrenia;
- has any medical or physical conditions that would preclude participation in an fMRI study (e.g., orthodontic braces);
- is currently receiving psychotherapy or electroconvulsive therapy (ECT);
- current opioid analgesics or systemic corticosteroid use for an acute medical condition or taken as needed;
- has had suicidal behaviors or significant suicidal ideation within the last six months.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Attention Bias Modification
Behavioral intervention designed to improved negative attention bias.
|
Behavioral intervention designed to decrease negative attention bias.
|
EXPERIMENTAL: Cognitive Control Training
Behavioral intervention designed to improve sustained attention.
|
Behavioral intervention designed to improve sustained attention.
|
NO_INTERVENTION: Assessment Only
Assessment only with no active intervention.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Quick Inventory of Depression - Self Report (QIDS-SR)
Time Frame: Change in QIDS-SR from baseline to Week 4 to measure change in self-reported depression.
|
16-item self-report measure of depression symptom severity
|
Change in QIDS-SR from baseline to Week 4 to measure change in self-reported depression.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mood and Anxiety Symptoms Questionnaire-Short Form (MASQ-SF)
Time Frame: Change in MASQ-SF from baseline to Week 4 to measure change in self-reported depression.
|
30-item self-report measure of negative affect symptoms
|
Change in MASQ-SF from baseline to Week 4 to measure change in self-reported depression.
|
Hamilton Depression Rating Scale - 17 Item (HAMD-17)
Time Frame: Change in HAMD-17 from baseline to Week 4 to measure change in interviewer-rated depression.
|
17-item clinician-administered measure of depression symptom severity
|
Change in HAMD-17 from baseline to Week 4 to measure change in interviewer-rated depression.
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Attention bias (eye tracking)
Time Frame: Change in attention bias from baseline to Week 4 to measure change in negative attention bias.
|
Primary ABM treatment target
|
Change in attention bias from baseline to Week 4 to measure change in negative attention bias.
|
Resting State (fMRI)
Time Frame: Change in resting state fMRI from baseline to Week 4 to measure change connectivity in frontal-parietal brain circuitry.
|
Resting state functional connectivity
|
Change in resting state fMRI from baseline to Week 4 to measure change connectivity in frontal-parietal brain circuitry.
|
Psychomotor vigilance test (PVT)
Time Frame: Change in PVT from baseline to Week 4 to measure change in sustained attention.
|
Behavioral assessment of sustained attention
|
Change in PVT from baseline to Week 4 to measure change in sustained attention.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Beevers CG, Clasen PC, Enock PM, Schnyer DM. Attention bias modification for major depressive disorder: Effects on attention bias, resting state connectivity, and symptom change. J Abnorm Psychol. 2015 Aug;124(3):463-75. doi: 10.1037/abn0000049.
- Beevers CG, Hsu KJ, Schnyer DM, Smits JAJ, Shumake J. Change in negative attention bias mediates the association between attention bias modification training and depression symptom improvement. J Consult Clin Psychol. 2021 Oct;89(10):816-829. doi: 10.1037/ccp0000683.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
September 1, 2017
Primary Completion (ACTUAL)
September 26, 2019
Study Completion (ACTUAL)
September 26, 2019
Study Registration Dates
First Submitted
August 17, 2016
First Submitted That Met QC Criteria
August 22, 2016
First Posted (ESTIMATE)
August 26, 2016
Study Record Updates
Last Update Posted (ACTUAL)
October 16, 2019
Last Update Submitted That Met QC Criteria
October 14, 2019
Last Verified
October 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 201600258
- R33MH109600-01A1 (NIH)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
De-identified data will be made available upon study completion.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Depression
-
ProgenaBiomeRecruitingDepression | Depression, Postpartum | Depression, Anxiety | Depression Moderate | Depression Severe | Clinical Depression | Depression in Remission | Depression, Endogenous | Depression ChronicUnited States
-
Washington University School of MedicineCompletedTreatment Resistant Depression | Late Life Depression | Geriatric Depression | Refractory Depression | Therapy-Resistant DepressionUnited States, Canada
-
Kintsugi Mindful Wellness, Inc.Sonar Strategies; Vituity PsychiatryRecruitingDepression | Depression Moderate | Depression Severe | Depression MildUnited States
-
University of California, San FranciscoRecruitingDepression Moderate | Depression Mild | Depression, TeenUnited States
-
University GhentUniversiteit Antwerpen; Janssen-Cilag Ltd.RecruitingDepression Moderate | Depression Severe | Depression MildBelgium
-
Baylor College of MedicineUniversity of TexasRecruitingDepression | Depression Moderate | Depression Severe | Suicide and Self-harm | Depression in Adolescence | Depression MildUnited States
-
University of Cape TownNational Institute of Mental Health (NIMH)CompletedPostpartum Depression | Clinical Depression | Moderate DepressionSouth Africa
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; National Institute of Mental...CompletedMajor Depressive Disorder | Treatment Resistant Depression | Treatment-Refractory Depression | Late Life Depression | Geriatric DepressionUnited States, Canada
-
Northern Illinois UniversityUniversity Autonoma de Santo DomingoTerminatedDepression Moderate | Depression MildUnited States, Dominican Republic
-
Gerbera Therapeutics, Inc.Not yet recruitingPostpartum Depression | Depression, Postpartum | Postnatal Depression | Post-partum Depression | Post-Natal DepressionUnited States
Clinical Trials on Attention Bias Modification
-
University of Texas at AustinArcade TherapeuticsNot yet recruiting
-
University of OsloDiakonhjemmet Hospital; University of Oxford; ExtrastiftelsenCompletedMajor Depressive DisorderNorway
-
University of OsloDiakonhjemmet Hospital; University of Oxford; Sorlandet Hospital HFCompleted
-
Florida State UniversitySan Diego State UniversityCompleted
-
Hunan Normal UniversityCompletedDepressive Disorder, MajorChina
-
University of Nebraska LincolnCompletedPosttraumatic Stress DisorderUnited States
-
University of Texas at TylerPsi Chi; Sarah Sass, PhDRecruiting
-
Humboldt-Universität zu BerlinCompletedObsessive-Compulsive DisorderGermany
-
Tel Aviv UniversityCompletedSocial Anxiety | Social Anxiety Disorder | Social Anxiety Disorder (Social Phobia)Israel
-
Northern Michigan UniversityNational Institute of Mental Health (NIMH)Completed